United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Friday, November 13th. The shares were sold at an average price of $592.42, for a total transaction of $5,627,990.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $192,206,522.06. This represents a 2.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

United Therapeutics Stock Down 0.6%

Shares of UTHR stock traded down $3.29 during trading hours on Monday, hitting $587.88. 424,498 shares of the company’s stock traded hands, compared to its average volume of 553,937. The stock’s fifty day simple moving average is $542.60 and its two-hundred day simple moving average is $536.37. United Therapeutics Corporation has a 12-month low of $455.63 and a 12-month high of $614.23. The stock has a market cap of $25.04 billion, a price-to-earnings ratio of 22.18, a PEG ratio of 3.93 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The company had revenue of $832.50 million during the quarter, compared to analysts’ expectations of $781.14 million. During the same quarter in the previous year, the company earned $7.16 EPS. The business’s quarterly revenue was up 4.1% on a year-over-year basis. On average, equities analysts forecast that United Therapeutics Corporation will post 25.08 earnings per share for the current fiscal year.

United Therapeutics declared that its Board of Directors has initiated a stock repurchase program on Thursday, October 22nd that permits the company to repurchase $2 billion in shares. This repurchase authorization permits the biotechnology company to repurchase up to 8.3% of its shares through open market purchases. Share repurchase programs are generally a sign that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several research reports. Morgan Stanley raised their target price on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 28th. HC Wainwright started coverage on United Therapeutics in a research note on Monday, November 9th. They issued a “buy” rating and a $660.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $850.00 price target on shares of United Therapeutics in a report on Monday, October 26th. Finally, UBS Group set a $725.00 price objective on United Therapeutics in a research note on Monday, October 19th. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $676.40.

View Our Latest Stock Analysis on UTHR

Institutional Trading of United Therapeutics

Hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in United Therapeutics in the 2nd quarter worth approximately $2,868,735,000. Janus Henderson Group PLC lifted its holdings in shares of United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after buying an additional 70,829 shares during the period. Jupiter Topco LLC acquired a new position in United Therapeutics in the second quarter valued at approximately $450,140,000. First Trust Advisors LP boosted its holdings in United Therapeutics by 40.4% during the third quarter. First Trust Advisors LP now owns 349,666 shares of the biotechnology company’s stock worth $189,480,000 after buying an additional 100,610 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of United Therapeutics during the 2nd quarter valued at about $159,522,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.

Featured Articles

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.